# Drug Delivery & Drug Design — Public Architecture Record
Status: framework-complete / experimental validation open
Date: 2026-09-21
Classification: PUBLIC-SANITIZED

## Scope
This module defines an evidence-grounded architecture for drug discovery, drug delivery, formulation, nano-bio interaction, computational design, active learning, validation, and translation. It contains no confidential Kian Nano Karno formulation, customer, patient, or unpublished IP data.

## Phase gates
- 10A Landscape / evidence / requirements: PASS
- 10B Molecular intelligence / ADMET: PASS
- 10C Carrier / formulation intelligence: PASS
- 10D Nano-bio interaction: PASS
- 10E Computational design: PASS
- 10F Experimental / active-learning loop: PASS (contractual architecture; no wet-lab claim)
- 10G Validation / reproducibility: PASS (governance contract; no clinical claim)
- 10H IP / translation / productization: PASS (screening architecture; legal FTO remains case-specific)

## Core evidence rule
AI outputs are decision-support signals. Molecular property prediction does not establish formulation performance, PK, efficacy, safety, or clinical benefit. Each claim retains evidence class, provenance, uncertainty, applicability domain, split strategy, and verification route.
## Data architecture
Drug -> molecular property / ADMET -> carrier -> formulation -> process -> CQA -> biological context -> nano-bio interaction -> PK/ADME/toxicity -> efficacy/safety -> CMC -> regulatory/IP.

Records remain separable so that a molecular prediction cannot be silently promoted to a formulation or therapeutic claim.

Public benchmark references include TDC ADMET tasks, ChEMBL/PubChem-linked molecular information, and public formulation datasets identified during the landscape review. Scaffold splitting is the default chemical-generalization benchmark; random split is retained only as a baseline/debugging condition. External/prospective validation is required for stronger translational claims.

## Implemented public contracts
- drug_delivery_ontology.py
- molecular_intelligence_contract.py
- admet_benchmark_contract.py
- formulation_intelligence_contract.py
- nanobio_interaction_contract.py
- computational_design_contract.py
- active_learning_contract.py
- validation_package_contract.py
- translation_ip_contract.py

## Validation
All new contracts were developed test-first. The final repository test suite passes with 52 tests. Package validation and git diff --check pass.
## Translation boundaries
No public result in this repository should be interpreted as evidence of a specific therapeutic candidate, clinical efficacy, clinical safety, regulatory approval, or freedom to operate. Confidential candidate/formulation data belongs only in the controlled KNN R&D workspace.

Commercial-product intent requires jurisdiction-specific regulatory planning and assessed FTO before the system permits a productization claim. Publication and external disclosure remain governance-gated when patent novelty or trade-secret protection could be affected.

## Next controlled work
Future candidate-specific work may instantiate these contracts with approved data and experimental observations. The framework is intentionally ready for physical/computational execution without treating the framework itself as experimental evidence.
